2/2-Antipsychotic Effects of Oxytocin
2/2-催产素的抗精神病作用
基本信息
- 批准号:8299491
- 负责人:
- 金额:$ 30.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-11 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAntipsychotic AgentsCaliforniaChronicClinicalClinical TrialsCognitiveCognitive deficitsDevelopmentDiseaseDoseDouble-Blind MethodDrug FormulationsDrug KineticsEffectivenessExperimental DesignsGoalsHormonesInterventionIntervention StudiesInvestigational DrugsLeadMarketingMemoryMental disordersNervous System PhysiologyNeuraxisNeurohormonesOxytocinPathway interactionsPatientsPeptidesPerformancePharmaceutical PreparationsPharmacodynamicsPhasePilot ProjectsPlacebosPlayPopulationPsychotic DisordersRandomizedRecruitment ActivityRegistriesRegulationResearchRoleSafetySample SizeSamplingSchizophreniaShort-Term MemorySiteStudy SubjectSymptomsTestingTherapeuticTherapeutic EffectTimeVerbal Learningbasecognitive functiondrug candidateefficacy testingfollow-upimprovedinnovationinterestmemory recallneuropsychiatrynovelplacebo controlled studyresearch studytreatment duration
项目摘要
DESCRIPTION (provided by applicant): The peptide neurohormone, oxytocin plays a critical role in the regulation of a number of diverse central nervous system functions, which are highly relevant to schizophrenia. Several studies using animal models of psychosis indicate that oxytocin produces antipsychotic-like effects. A recent, small, proof-of-concept study, found that schizophrenia subjects taking intranasal oxytocin (40 IU BID) as an adjunct to existing antipsychotic drugs for 3 weeks had significantly reduced symptoms of psychosis and improved memory compared to subjects taking placebo. We now propose to perform a follow-up study adding a higher dose and increasing the duration of treatment with the goal of replicating and extending the promising preliminary findings. Specifically, the proposed study will test the efficacy and safety of 6-weeks of daily intranasal oxytocin (40 IU BID or 80 IU BID compared to placebo on core symptoms of schizophrenia and on cognitive deficits associated with the disorder. It is hypothesized that both oxytocin doses will improve symptoms and cognitive function with the higher dose (80 IU BID) producing stronger effects. The proposed study will provide critical efficacy, dosing and safety information regarding the feasibility of developing oxytocin as a treatment for schizophrenia.
描述(由申请人提供):肽神经激素催产素在调节多种中枢神经系统功能中发挥着关键作用,这些功能与精神分裂症高度相关。几项使用精神病动物模型的研究表明,催产素会产生类似抗精神病药的作用。最近的一项小型概念验证研究发现,与服用安慰剂的受试者相比,服用鼻内催产素(40 IU BID)作为现有抗精神病药物的辅助药物连续 3 周的精神分裂症受试者可显着减轻精神病症状并改善记忆力。我们现在建议进行一项后续研究,增加更高的剂量并延长治疗持续时间,以复制和扩展有希望的初步结果。具体来说,拟议的研究将测试为期 6 周的每日鼻内催产素(40 IU BID 或 80 IU BID 与安慰剂相比)对精神分裂症核心症状和与该疾病相关的认知缺陷的有效性和安全性。据推测,两种催产素剂量都会改善症状和认知功能,其中较高剂量(80 IU BID)会产生更强的效果。拟议的研究将提供 有关开发催产素治疗精神分裂症的可行性的关键功效、剂量和安全性信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN G POTKIN其他文献
STEVEN G POTKIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN G POTKIN', 18)}}的其他基金
CSF-enhanced-aggregation biomarker for Huntingtons disease
亨廷顿病的脑脊液增强聚集生物标志物
- 批准号:
8915257 - 财政年份:2014
- 资助金额:
$ 30.98万 - 项目类别:
TRANSDISCIPLINARY IMAGING GENETICS CENTER (RMI)
跨学科影像遗传学中心 (RMI)
- 批准号:
8363436 - 财政年份:2011
- 资助金额:
$ 30.98万 - 项目类别:
TRANSDISCIPLINARY IMAGING GENETICS CENTER (1 OF 2)(RMI)
跨学科成像遗传学中心(2 中的 1)(RMI)
- 批准号:
8171050 - 财政年份:2010
- 资助金额:
$ 30.98万 - 项目类别:
TRANSDISCIPLINARY IMAGING GENETICS CENTER (1 OF 2)(RMI)
跨学科成像遗传学中心(2 中的 1)(RMI)
- 批准号:
7955659 - 财政年份:2009
- 资助金额:
$ 30.98万 - 项目类别:
相似海外基金
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
- 批准号:
10661090 - 财政年份:2022
- 资助金额:
$ 30.98万 - 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
- 批准号:
10501196 - 财政年份:2022
- 资助金额:
$ 30.98万 - 项目类别:
Possible mechanism of action of metabolic syndrome induction in patients treated with atypical antipsychotic agents
使用非典型抗精神病药物治疗的患者诱导代谢综合征的可能作用机制
- 批准号:
22590157 - 财政年份:2010
- 资助金额:
$ 30.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The use of atypical antipsychotic agents and the risk of breast cancer
非典型抗精神病药物的使用和乳腺癌的风险
- 批准号:
192724 - 财政年份:2009
- 资助金额:
$ 30.98万 - 项目类别:
Operating Grants
Indolobenzox- and Thiazepines as Atypical Antipsychotic Agents
吲哚苯氧和硫氮卓类药物作为非典型抗精神病药
- 批准号:
7539253 - 财政年份:2008
- 资助金额:
$ 30.98万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7676049 - 财政年份:2007
- 资助金额:
$ 30.98万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7626881 - 财政年份:2007
- 资助金额:
$ 30.98万 - 项目类别:
Ectopic activators of M1 as novel antipsychotic agents
M1 异位激活剂作为新型抗精神病药物
- 批准号:
7333930 - 财政年份:2007
- 资助金额:
$ 30.98万 - 项目类别:
Muscarinic receptor activators as antipsychotic agents
作为抗精神病药物的毒蕈碱受体激活剂
- 批准号:
7034693 - 财政年份:2006
- 资助金额:
$ 30.98万 - 项目类别:
Muscarinic receptor activators as novel antipsychotic agents
毒蕈碱受体激活剂作为新型抗精神病药
- 批准号:
7163800 - 财政年份:2006
- 资助金额:
$ 30.98万 - 项目类别: